4.06
-0.24(-5.58%)
Currency In USD
| Previous Close | 4.3 |
| Open | 4.28 |
| Day High | 4.29 |
| Day Low | 4.04 |
| 52-Week High | 11.88 |
| 52-Week Low | 1.06 |
| Volume | 1.18M |
| Average Volume | 1.03M |
| Market Cap | 286.59M |
| PE | -2.37 |
| EPS | -1.71 |
| Moving Average 50 Days | 5.48 |
| Moving Average 200 Days | 6.35 |
| Change | -0.24 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $159.28 as of December 04, 2024 at a share price of $4.06. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 3 years ago, it would be worth $113.88 as of December 04, 2024 at a share price of $4.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
GlobeNewswire Inc.
Nov 20, 2024 12:00 PM GMT
Hoerter Brings Over Three Decades of Oncology Commercialization and Leadership Experience Appointment Underscores Continued Transformation of Board to Lead C4T into Next Phase of Pipeline Progress WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) --
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial
GlobeNewswire Inc.
Nov 06, 2024 12:00 PM GMT
Clinical Development Initiated in Greater China by Partner Betta PharmaceuticalsWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing target
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
GlobeNewswire Inc.
Nov 05, 2024 2:00 PM GMT
C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein d